N
NHJ
Northern Health Journal — UK Edition

Evidence-Based Metabolic Health

Insights from UK research and the NHS for healthier living

Featured Article
Oxford Biobank Breakthrough: Metabolic Phenotyping Predicts Peptide Therapy Response
Research
11 min read

Oxford Biobank Breakthrough: Metabolic Phenotyping Predicts Peptide Therapy Response

University of Oxford researchers have used UK Biobank data to identify five distinct metabolic phenotypes that predict not only disease trajectory but also individual response to peptide-based therapies — from GLP-1 receptor agonists to NAD+ precursors and regenerative peptides.

Prof. Catherine Wells
Professor of Metabolic Medicine, University of Oxford
Read article
Latest Articles
AI-Driven Peptide Therapy: How Machine Learning Is Personalising Metabolic Treatment in the NHS
Technology
5
8 min read

AI-Driven Peptide Therapy: How Machine Learning Is Personalising Metabolic Treatment in the NHS

NHS Digital and UCL researchers have developed AI algorithms that predict individual responses to peptide-based metabolic therapies, enabling precision dosing of GLP-1 receptor agonists and identifying which patients will benefit most from emerging peptide compounds.

Dr. Oliver Chen
Neuropeptides and the Metabolic-Psychiatric Connection: From Semax to GLP-1 in Brain Health
Mental Health
4
10 min read

Neuropeptides and the Metabolic-Psychiatric Connection: From Semax to GLP-1 in Brain Health

Maudsley Hospital researchers explore how neuropeptides — including Semax, Selank, and GLP-1 receptor agonists — are revealing the deep biological connection between metabolic dysfunction and psychiatric disorders, with implications for treating both conditions simultaneously.

Dr. Priya Nair
Gut Peptides and the Microbiome: How BPC-157 and Endogenous Peptides Are Transforming Metabolic Gastroenterology
Nutrition
3
9 min read

Gut Peptides and the Microbiome: How BPC-157 and Endogenous Peptides Are Transforming Metabolic Gastroenterology

King's College London researchers reveal how gastric peptides — including the remarkable Body Protection Compound-157 (BPC-157) — interact with the gut microbiome to regulate metabolic function, opening new frontiers in treating metabolic syndrome through the gut-brain-metabolism axis.

Dr. Sarah Pemberton
The Incretin Peptide Revolution: How Semaglutide and Tirzepatide Are Rewriting Metabolic Medicine
Pharmacology
2
11 min read

The Incretin Peptide Revolution: How Semaglutide and Tirzepatide Are Rewriting Metabolic Medicine

Imperial College researchers explain the molecular mechanisms behind GLP-1 and dual GIP/GLP-1 receptor agonists, why subcutaneous peptide delivery achieves superior bioavailability, and what the next generation of incretin-based compounds could mean for metabolic health.

Prof. James Harrington
NHS 2026: How Peptide-Based Therapies Are Reshaping Metabolic Healthcare in Britain
NHS Policy
1
9 min read

NHS 2026: How Peptide-Based Therapies Are Reshaping Metabolic Healthcare in Britain

NHS England's updated metabolic health framework places GLP-1 receptor agonists, dual-incretin peptides, and emerging bioactive peptide compounds at the centre of a new treatment paradigm — signalling a profound shift toward peptide-based precision medicine.

Dr. Eleanor Whitfield